VBI Non Operating Income Net Other vs Total Operating Expenses Analysis
VBIV Stock | USD 0.63 0.02 3.08% |
VBI Vaccines financial indicator trend analysis is much more than just breaking down VBI Vaccines prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether VBI Vaccines is a good investment. Please check the relationship between VBI Vaccines Non Operating Income Net Other and its Total Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.
Non Operating Income Net Other vs Total Operating Expenses
Non Operating Income Net Other vs Total Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of VBI Vaccines Non Operating Income Net Other account and Total Operating Expenses. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between VBI Vaccines' Non Operating Income Net Other and Total Operating Expenses is -0.58. Overlapping area represents the amount of variation of Non Operating Income Net Other that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of VBI Vaccines, assuming nothing else is changed. The correlation between historical values of VBI Vaccines' Non Operating Income Net Other and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Operating Income Net Other of VBI Vaccines are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Non Operating Income Net Other i.e., VBI Vaccines' Non Operating Income Net Other and Total Operating Expenses go up and down completely randomly.
Correlation Coefficient | -0.58 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Non Operating Income Net Other
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most indicators from VBI Vaccines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VBI Vaccines current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.At this time, VBI Vaccines' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 35.9 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.76) in 2024.
2023 | 2024 (projected) | Non Recurring | 5.7M | 5.0M | Reconciled Depreciation | 2.0M | 1.6M |
VBI Vaccines fundamental ratios Correlations
Click cells to compare fundamentals
VBI Vaccines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
VBI Vaccines fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 122.2M | 209.4M | 210.3M | 155.1M | 87.0M | 73.5M | |
Total Stockholder Equity | 88.3M | 171.7M | 143.9M | 64.2M | 7.5M | 7.2M | |
Property Plant And Equipment Net | 10.2M | 10.7M | 11.0M | 12.3M | 11.9M | 21.9M | |
Net Debt | (29.4M) | (92.9M) | (89.9M) | (10.4M) | 29.4M | 30.8M | |
Retained Earnings | (262.4M) | (308.6M) | (378.4M) | (489.6M) | (582.4M) | (553.3M) | |
Cash | 44.2M | 93.8M | 121.7M | 62.6M | 23.7M | 28.9M | |
Non Current Assets Total | 75.2M | 77.3M | 80.0M | 77.4M | 50.7M | 42.9M | |
Non Currrent Assets Other | 2.1M | 2.2M | 4.6M | 4.7M | 1.2M | 992.6K | |
Cash And Short Term Investments | 44.2M | 119.1M | 121.7M | 62.6M | 23.7M | 31.5M | |
Common Stock Shares Outstanding | 4.0M | 7.3M | 8.5M | 8.6M | 15.6M | 16.4M | |
Liabilities And Stockholders Equity | 122.2M | 209.4M | 210.3M | 155.1M | 87.0M | 73.5M | |
Other Current Assets | 450K | 1.3M | 2.2M | 8.4M | 2.8M | 2.9M | |
Other Stockholder Equity | 66.4M | 75.5M | 81.6M | 90.0M | 107.4M | 112.8M | |
Total Liab | 33.9M | 37.7M | 66.4M | 90.9M | 79.4M | 83.4M | |
Property Plant And Equipment Gross | 11.7M | 12.3M | 19.3M | 23.6M | 22.3M | 27.7M | |
Total Current Assets | 47.0M | 132.0M | 130.3M | 77.7M | 36.2M | 33.0M | |
Total Current Liabilities | 29.8M | 17.3M | 32.6M | 36.9M | 75.7M | 79.5M | |
Accounts Payable | 1.1M | 3.7M | 4.3M | 13.0M | 6.4M | 6.8M | |
Net Receivables | 201K | 77K | 8K | 94K | 1.3M | 1.3M | |
Non Current Liabilities Total | 4.2M | 20.3M | 33.8M | 54.0M | 3.7M | 3.5M | |
Accumulated Other Comprehensive Income | (752K) | 1.3M | (1.6M) | 21.4M | 28.3M | 29.7M | |
Other Assets | 620K | 2.2M | 1.3M | 1.4M | 1.0 | 0.95 | |
Short Long Term Debt Total | 14.8M | 944K | 31.8M | 52.2M | 53.0M | 55.7M | |
Inventory | 1.1M | 2.2M | 2.6M | 6.6M | 8.5M | 8.9M | |
Other Current Liab | 12.9M | 12.4M | 26.9M | 22.6M | 6.7M | 5.7M | |
Short Term Debt | 14.8M | 944K | 839K | 972K | 51.7M | 54.3M | |
Common Stock Total Equity | 285.0M | 403.5M | 442.2M | 442.3M | 508.7M | 260.5M | |
Common Stock | 285.0M | 403.5M | 442.2M | 442.3M | 454.2M | 247.1M | |
Net Tangible Assets | 25.3M | 107.3M | 79.5M | 3.7M | 4.2M | 4.0M | |
Current Deferred Revenue | 882K | 255K | 526K | 409K | 10.9M | 11.4M | |
Intangible Assets | 60.8M | 62.2M | 62.1M | 58.3M | 36.5M | 47.5M | |
Property Plant Equipment | 11.7M | 10.7M | 11.0M | 12.3M | 14.1M | 14.8M | |
Other Liab | 3.4M | 3.4M | 2.9M | 2.7M | 3.1M | 2.7M | |
Short Long Term Debt | 1.6M | 1.1M | 14.8M | 50.8M | 58.4M | 61.3M | |
Capital Surpluse | 66.4M | 75.5M | 81.6M | 90.0M | 103.5M | 75.2M | |
Good Will | 8.3M | 2.2M | 2.3M | 2.1M | 1.1M | 1.1M | |
Retained Earnings Total Equity | (262.4M) | (308.6M) | (378.4M) | (489.6M) | (440.6M) | (418.6M) |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.03) | Revenue Per Share 0.558 | Quarterly Revenue Growth 1.911 | Return On Assets (0.29) | Return On Equity (2.59) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.